Adapting Traditional Drug Development Methods for Epigenetic Therapies- Peter Staller

Gerald Clarke

Peter Staller Director of Oncology Research at Epitherapeutics talks to Pharma IQ about the differences between traditional drug development techniques and those required for development of a epigenetic therapy. He also discusses epigenetics as a growing area for finding druggable targets and the maturity of the field. Have Your Say Rate this feature and give us your feedback in the comments section below  
To continue reading this story get free access